| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10009794 | HBV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS10036366 | HBV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058841 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058842 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058843 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058844 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058845 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058846 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058847 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
| TVIS30058848 | HIV | ENSG00000114200.10 | protein_coding | BCHE | No | No | 590 | P06276 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | BCHE |
|---|---|
| DrugBank ID | DB00674 |
| Drug Name | Galantamine |
| Target ID | BE0002180 |
| UniProt ID | P06276 |
| Regulation Type | inhibitor |
| PubMed IDs | 17159811; 11888344; 19811027; 12177686 |
| Citations | Svoboda Z, Kvetina J, Kunesova G, Herink J, Bajgar J, Bartosova L, Zivny P, Palicka V: Effect of galantamine on acetylcholinesterase and butyrylcholinesterase activities in the presence of L-carnitine in rat selected brain and peripheral tissues. Neuro Endocrinol Lett. 2006 Dec;27 Suppl 2:183-6.@@Giacobini E: Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging. 2001;18(12):891-8.@@Wilkinson DG: Galantamine: a new treatment for Alzheimer's disease. Expert Rev Neurother. 2001 Nov;1(2):153-9. doi: 10.1586/14737175.1.2.153.@@Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. |
| Groups | Approved |
| Direct Classification | Galanthamine-type amaryllidaceae alkaloids |
| SMILES | [H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3 |
| Pathways | |
| PharmGKB | PA449726 |
| ChEMBL | CHEMBL659 |
